完整後設資料紀錄
DC 欄位語言
dc.contributor.authorHsu, Nan-Yungen_US
dc.contributor.authorWu, Jeng-Yuanen_US
dc.contributor.authorLiu, Xiyongen_US
dc.contributor.authorYen, Yunen_US
dc.contributor.authorChen, Chih-Yien_US
dc.contributor.authorChou, Ming-Chihen_US
dc.contributor.authorLin, Chun-Hsuanen_US
dc.contributor.authorLee, Hueien_US
dc.contributor.authorCheng, Ya-Wenen_US
dc.date.accessioned2014-12-08T15:26:25Z-
dc.date.available2014-12-08T15:26:25Z-
dc.date.issued2011-10-01en_US
dc.identifier.issn0250-7005en_US
dc.identifier.urihttp://hdl.handle.net/11536/18749-
dc.description.abstractOverexpression of ribonucleotide reductase M2 (hRRM2) and p53-dependent RR small subunit (p53R2) has been correlated with tumor malignancy and progression in several types of cancer. The aim of this study was to determine the association of p53R2/hRRM2 expression with clinicopathological characteristics of stage I and II non-small cell lung cancer (NSCLC). Immunohistochemistry was conducted on a tissue array that included 92 samples. Correlations between hRRM2 and p53R2 expression and clinicopathological factors, recurrence/metastasis, and outcomes were analyzed. The analyses revealed that there was no correlation between p53R2 expression and clinicopathological factors; hRRM2 was only positively related to poor tumor differentiation (p=0.006). Regarding overall survival during the follow-up period, patients with p53R2+/hRRM2- tumors had the best outcomes (p<0.01). Multivariant Cox analysis revealed that p53R2 (risk=0.232, 95% CI=0.086-0.626, p=0.004) not only served as a prognostic biomarker to predict survival, but also as an independent biomarker to predict disease-free survival (risk=0.545, 95% CI=0.301-0.987, p=0.045) of patients with NSCLC. Therefore, we consider that the expression of p53R2 can be used not only as a biomarker for overall survival, but also as an indicator for tumor recurrence. Based on our finding, p53R2 expression seems more important than that of hRRM2 in prognosis of early-stage lung cancer.en_US
dc.language.isoen_USen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectribonucleotide reductaseen_US
dc.subjectp53R2en_US
dc.subjecthRRM2en_US
dc.titleExpression Status of Ribonucleotide Reductase Small Subunits hRRM2/p53R2 as Prognostic Biomarkers in Stage I and II Non-small Cell Lung Canceren_US
dc.typeArticleen_US
dc.identifier.journalANTICANCER RESEARCHen_US
dc.citation.volume31en_US
dc.citation.issue10en_US
dc.citation.spage3475en_US
dc.citation.epage3481en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000295667700049-
dc.citation.woscount8-
顯示於類別:期刊論文


文件中的檔案:

  1. 000295667700049.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。